Abstract 17220: Effects of the Oral Adsorbent of AST-120 in Patients with both Chronic Heart Failure and Chronic Kidney Disease
Miki Imazu(National Cerebral and Cardiovascular Center), Masafumi Kitakaze(Hanwa Memorial Hospital), Akira Funada(National Cerebral and Cardiovascular Center), Hiroshi Asanuma(Meiji University of Integrative Medicine), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Takuya Hasegawa(Tokyo Institute of Technology), Hiroyuki Takahama(Tohoku University), Masanori Asakura(National Cerebral and Cardiovascular Center), Takahiro Ohara(Tohoku Medical and Pharmaceutical University), Atsushi Nakano(National Cerebral and Cardiovascular Center), Shin Ito(National Cerebral and Cardiovascular Center), Toshisuke Morita(Toho University), Yasuo Sugano(keiyu Hospital)
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
Magnetic properties of Mn-doped ZnO
|Applied Physics Letters|2001|663
High throughput fabrication of transition-metal-doped epitaxial ZnO thin films: A series of oxide-diluted magnetic semiconductors and their properties
|Applied Physics Letters|2001|597
Right Ventricular Function in Heart Failure With Preserved Ejection Fraction
|Circulation|2014|456